HSA Grants Conditional Approval of Remdesivir for Treatment of COVID-19 Infection
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee, has today granted conditional approval for Gilead Sciences Singapore Pte Ltd?s (Gilead) Veklury? (remdesivir). This will allow infectious diseases specialists to administer remdesivir for the treatment of adult patients with COVID-19 infection, who:
- Have oxygen saturation less than or equal to 94%, or;
- Require supplemental oxygen, or;
- Require more intensive breathing support such as extracorporeal membrane oxygenation or?invasive?mechanical ventilation.
?Consumer, Healthcare professional, Industry member, Therapeutic Products
Published:?10 Jun 2020